Regulatory & Reimbursement Newsletter

The Acting Director of CDER is retiring, the FDA unveiled a new priority voucher program, conducted a CEO listening tour across the country, and launched an agency-wide artificial intelligence tool, and more.

FDA reveals FY26 budget, plans to expand unannounced foreign inspections, increase the use of AI in its scientific reviews and enhance state drug importation programs, and more.